Ruiyi Pharma Completes Tens of Millions of Yuan Strategic Financing to Accelerate Scale Expansion and Business Development, Files IPO Prospectus

VCBeat has learned that Shanghai Ruiyi Medical Technology Co., Ltd. (“Ruiyi Tech,” NEEQ Code: 836193), a leading enterprise in molecular building blocks, recentlyAnnounced the completion of a strategic private placement worth tens of millions of yuan, led by Hygeia Capital and participated in by Hongbo Capital.Ruiyi Technology stated, “This strategic capital increase will further strengthen the Company’s financial position, facilitate more effective scale expansion and business development, and enhance its overall competitiveness.”

Ruiyi Technology was founded by Mr. Xue Song in 2006, with its core business focused on providing customized contract research and manufacturing services for pharmaceutical production. Ruiyi Technology possesses multiple specialized technologies and has developed several domestically first-of-their-kind general-purpose reagents and new drug molecular building blocks. Its flagship products have been exclusively supplied to numerous large international pharmaceutical companies for an extended period, and the company maintains long-term, close collaborative relationships with renowned new drug R&D service providers both in China and abroad. After years of development, Ruiyi Technology has grown into a CDMO enterprise serving well-known pharmaceutical companies domestically and internationally, providing key intermediates and functional molecular building blocks for new drugs from clinical Phase I, II, and III trials through to commercialization.

Mr. Xue Song, Founder and Chairman of Ruiyi TechnologyIndicates: It is a great honor to receive joint investment from Hygeia Capital and Hongbo Capital. In the future, Ruiyi Medical Technology will focus on strengthening R&D and production quality management, further enhance the development and reserve of new projects, and strive to provide better services to both new and existing customers.

Dr. Du Jiangbo, Partner at Hygeia CapitalStatement: It is a great honor to participate in Ruiyi Technology’s current strategic private placement. Having cultivated the domestic molecular building blocks sector for many years, Ruiyi Technology has earned consistent acclaim from numerous clients both in China and abroad, thanks to its distinctive technological advantages and robust product quality, while maintaining sustained high-speed growth in performance. We look forward to seeing Ruiyi Technology, under the leadership of Mr. Xue, list on the capital market at an early date following this strategic private placement, and continue to provide high-quality products and services to customers worldwide as always.

Mr. Qi Keren, Founder and General Manager of Hongbo Capitalindicate: It is a great honor to participate in Ruiyi Medical Technology’s strategic private placement. As a CDMO enterprise serving innovative drug R&D, Ruiyi Medical Technology possesses core process development capabilities and large-scale production capacity, and has established in-depth cooperative relationships with numerous renowned pharmaceutical companies and new drug R&D service providers both domestically and internationally, boasting broad prospects for future development. We also look forward to establishing a comprehensive partnership with Ruiyi Medical Technology through this private placement, facilitating its rapid growth and making greater contributions to the nation’s pharmaceutical industry.

Hygeia Capital is aAdopting a dual-drive investment strategy of “VC Investment” + “Investment Banking Services,” this private equity fund focuses on the broader healthcare industry. Its management team possesses extensive background in the medical and health sectors as well as rich experience in equity investment. Hygeia Capital’s portfolio includes numerous high-quality enterprises such as Kindly Medical Devices (1501.HK) [interventional medical devices], Cofoe Medical [home-use medical devices], Besta CRO [clinical CRO], Velicure Biopharma [new drug R&D], ZhiDao Bio [new drug R&D], Zhongyi Anke [vaccine R&D], Respules Pharma [inhalation formulations], Haibowei Pharma [new drug R&D], Shengsi Bio [new drug R&D], Kaifu Pharma [new drug R&D], Huajian Future [new drug R&D], Junyue Pharma [device CRO], Xinnuo Medicine [animal experimentation center], and Ruiyi Tech [pharmaceutical CDMO].

Hongbo Capital is a private equity fund manager established jointly by state-owned financial institutions and an investment banking team. Adhering to the philosophy of strategic value-added investing, the company is committed to providing comprehensive financial services to its portfolio companies, including financing and investment, industry consolidation, and strategic planning.